What is the official website of Novartis Nederland - Neurologie ?

The official website of Novartis Nederland - Neurologie is http://www.zorgverlener.novartis.nl.

What is Novartis Nederland - Neurologie's cybersecurity risk score?

Novartis Nederland - Neurologie has an AI-generated cybersecurity risk score of 754 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Nederland - Neurologie experienced?

According to Rankiteo, Novartis Nederland - Neurologie currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Nederland - Neurologie been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Nederland - Neurologie has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Nederland - Neurologie have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Nederland - Neurologie is not certified under SOC 2 Type 1.

Does Novartis Nederland - Neurologie have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Nederland - Neurologie does not hold a SOC 2 Type 2 certification.

Does Novartis Nederland - Neurologie comply with GDPR ?

According to Rankiteo, Novartis Nederland - Neurologie is not listed as GDPR compliant.

Does Novartis Nederland - Neurologie have PCI DSS certification ?

According to Rankiteo, Novartis Nederland - Neurologie does not currently maintain PCI DSS compliance.

Does Novartis Nederland - Neurologie comply with HIPAA ?

According to Rankiteo, Novartis Nederland - Neurologie is not compliant with HIPAA regulations.

Does Novartis Nederland - Neurologie have ISO 27001 certification ?

According to Rankiteo,Novartis Nederland - Neurologie is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Nederland - Neurologie operate in ?

Novartis Nederland - Neurologie operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Nederland - Neurologie have ?

Novartis Nederland - Neurologie employs approximately None employees people worldwide.

Does Novartis Nederland - Neurologie own any subsidiaries ?

Novartis Nederland - Neurologie presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Nederland - Neurologie have ?

Novartis Nederland - Neurologie's official LinkedIn profile has approximately 2,099 followers.

What is the NAICS classification code for Novartis Nederland - Neurologie ?

Novartis Nederland - Neurologie is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Nederland - Neurologie have a Crunchbase profile ?

No, Novartis Nederland - Neurologie does not have a profile on Crunchbase.

Does Novartis Nederland - Neurologie have a LinkedIn profile ?

Yes, Novartis Nederland - Neurologie maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-nederland-neurologie.

How many cybersecurity incidents has Novartis Nederland - Neurologie experienced ?

As of July 12, 2026, Rankiteo reports that Novartis Nederland - Neurologie has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Nederland - Neurologie have ?

Novartis Nederland - Neurologie has an estimated 5,706 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Nederland - Neurologie faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

NNN

Boost Score +25 with badge (5 left)

754

/1000

Fair

779

/1000

Fair

Novartis Nederland - Neurologie Vendor Cyber Rating & Cyber Score

novartis.nl

Add Your Compliance Badge

Novartis heeft een 60-jarige geschiedenis in de neurowetenschappen. We bieden patiënten en artsen een groot assortiment aan geneesmiddelen voor multiple sclerose, de ziekte van Alzheimer, de ziekte van Parkinson, epilepsie, ADHD en migraine. Tevens hebben we producten in de pijplijn voor multiple sclerose, de ziekte van Alzheimer en neuromusculaire therapieën. Om hersenaandoeningen beter te begrijpen en geneesmiddelen met toegevoegde waarde te blijven ontwikkelen voor patiënten wereldwijd, maken we in ons onderzoek gebruik van de nieuwste inzichten in de menselijke genetica, nieuwe beeldvormende technologieën en andere nieuwe benaderingen. De richtlijnen van onze LinkedIn pagina kan je terugvinden op:

NNN A.I CyberSecurity Scoring

Scoring History

NNN

Novartis Nederland - Neurologie CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Nederland ...

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

NNN Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for NNN

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Nederland - Neurologie in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Nederland - Neurologie in 2026.

Incident Types NNN vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Nederland - Neurologie in 2026.

Incident History - NNN (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Nederland - Neurologie Subsidiaries

NNN

Pharmaceutical Manufacturing

Website: http://www.zorgverlener.novartis.nl

Company Size: 10,001+ employees

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - OncologiePharmaceutical Manufacturing

Novartis Nederland - Cardiovascular, Renal & MetabolismPharmaceutical Manufacturing

Novartis Nederland - DermatologiePharmaceutical Manufacturing

Novartis Nederland - ReumatologiePharmaceutical Manufacturing

Loading…

Novartis Nederland - Neurologie Similar Companies

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Loading…

NEWS

Novartis Nederland - Neurologie CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-58281

SUMMARY

Deserialization of untrusted data in Microsoft Edge (Chromium-based) allows an unauthorized attacker to execute code over a network.

Published

Date2026-07-11

Updated

Date2026-07-11

RISK INFORMATION (Score: 8.3)

cvss3

Base Score: 8.3

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:R/S:C/C:H/I:H/A:H

Impact Score

Exploitability

1.6

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-58281

CVE-2026-10660

SUMMARY

The Bluetooth BAP Broadcast Assistant GATT client in subsys/bluetooth/audio/bap_broadcast_assistant.c reassembled remote Broadcast Receive State data into a single file-static net_buf_simple (att_buf, BT_ATT_MAX_ATTRIBUTE_LEN = 512 bytes) shared by all connection instances, while the BUSY flag, long-read handle, and reset/offset state were per-connection. When the device acts as a Broadcast Assistant connected to multiple Scan Delegator peripherals, notification and long-read callbacks from different connections interleave on the shared buffer: the append in notify_handler (net_buf_simple_add_mem at the not-busy branch) performs no tailroom check, so receive-state notifications from two or more delegators accumulate on the same 512-byte buffer and, with a sufficiently large configured ATT MTU (BT_L2CAP_TX_MTU up to 2000) and two-to-three concurrent connections, write past the buffer into adjacent .bss (net_buf_simple_add only asserts in debug builds). Even below the overflow threshold, one connection's net_buf_simple_reset zeroes the shared length while another connection's reassembly and GATT read offset are in flight, mixing one peer's data into another's parse. A malicious or compromised Scan Delegator (or two colluding peers) over BLE can trigger this, causing out-of-bounds writes (memory corruption / denial of service) and cross-connection data corruption. The fix moves the buffer into the per-connection instance struct so each connection reassembles into its own buffer. Affects Zephyr releases shipping the Broadcast Assistant with the shared buffer, including v4.4.0 and earlier.

Published

Date2026-07-11

Updated

Date2026-07-11

RISK INFORMATION (Score: 6.4)

cvss3

Base Score: 6.4

Complexity: HIGH

CVSS:3.1/AV:A/AC:H/PR:N/UI:N/S:U/C:L/I:L/A:H

Impact Score

4.7

Exploitability

1.6

REFERENCES

CVE-2026-61870

SUMMARY

ImageMagick before 7.1.2-26 contains a memory leak vulnerability in the VIFF encoder when memory allocation fails. Attackers can trigger allocation failures by processing specially crafted VIFF images to exhaust available memory and cause denial of service.

Published

Date2026-07-11

Updated

Date2026-07-11

RISK INFORMATION (Score: 2.9)

cvss3

Base Score: 2.9

Complexity: HIGH

CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L

cvss4

Base Score: 2.1

Complexity: HIGH

CVSS:4.0/AV:L/AC:H/AT:P/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

1.4

REFERENCES

CVE-2026-61861

SUMMARY

ImageMagick before 7.1.2-26 contains a use-after-free vulnerability in the FormatMagickCaption method when memory allocation fails. Attackers can trigger memory allocation failures to cause a dangling pointer to reference freed memory, potentially enabling denial of service or code execution.

Published

Date2026-07-11

Updated

Date2026-07-11

RISK INFORMATION (Score: 3.7)

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L

cvss4

Base Score: 6.3

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:P/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.2

REFERENCES

CVE-2026-61858

SUMMARY

ImageMagick before 7.1.2-26 contains a policy bypass vulnerability in the APNG encoder and external delegates due to missing validation checks. Attackers can write files to disallowed paths by bypassing configured policy restrictions through the APNG encoding process.

Published

Date2026-07-11

Updated

Date2026-07-11

RISK INFORMATION (Score: 3.3)

cvss3

Base Score: 3.3

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:N

cvss4

Base Score: 4.8

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

1.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…